Search results for "Phenotype"

showing 10 items of 1875 documents

Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis.

2012

ABSTRACT Objective: Recent evidence suggests that intermediate-length polyglutamine (PolyQ) expansions in the ataxin-2 ( ATXN-2 ) gene are a risk factor for amyotrophic lateral sclerosis (ALS). This work was undertaken with the aim to investigate the frequency of ataxin-1 ( ATXN-1 ) and ATXN-2 PolyQ expansions in a cohort of patients with sporadic ALS (sALS) and patients with familial ALS (fALS) from southern Italy. Methods: We assessed the PolyQ lengths of ATXN-1 and ATXN-2 in 405 patients with sALS, 13 patients with fALS, and 296 unrelated controls without history of neurodegenerative disorders. Results: We found significantly higher intermediate PolyQ expansions ≥32 for ATXN-1 alleles an…

OncologyAdultMalemedicine.medical_specialtyGenotypeALS; ATXN-1; ATXN-2Ataxin 1Nerve Tissue ProteinsRisk FactorsInternal medicinemedicineHumansIn patientGenetic Predisposition to DiseaseAmyotrophic lateral sclerosisAlleleRisk factorAge of OnsetATXN-2ATXN-1AllelesAtaxin-1AgedAged 80 and overbiologybusiness.industryAmyotrophic Lateral SclerosisAge FactorsNuclear ProteinsMiddle Agedmedicine.diseaseIncreased riskPOLYGLUTAMINE EXPANSIONS; HEXANUCLEOTIDE REPEAT; ALS; TYPE-1; NEURODEGENERATION; PHENOTYPE; GENETICS; PROTEIN; C9ORF72; RISKAtaxinsItalyAtaxinCohortbiology.proteinFemaleSettore MED/26 - NeurologiaNeurology (clinical)ALSbusinessPeptidesTrinucleotide Repeat Expansion
researchProduct

Hypoxia and Aggressive Tumor Phenotype: Implications for Therapy and Prognosis

2008

Abstract Tumor hypoxia, mostly resulting from poor perfusion and anemia, is one of the key factors in inducing the development of cell clones with an aggressive and treatment-resistant phenotype that leads to rapid progression and poor prognosis. Studies in patients with solid tumors suggest that there is a range of hemoglobin (Hb) concentrations that is optimum for tumor oxygenation. When used to achieve an Hb level within this range, erythropoiesis-stimulating agents (ESAs) can be expected to increase tumor oxygenation, and this may favorably influence sensitivity to treatment as well as quality of life. There is no robust evidence that ESAs, when used as indicated, have a negative effect…

OncologyCancer Researchmedicine.medical_specialtyPathologyAnemiaCellHemoglobinsNeoplasmsInternal medicinemedicineHumansErythropoietinCell ProliferationTumor hypoxiabusiness.industryAnemiaCell DifferentiationHypoxia (medical)Tumor OxygenationHypoxia-Inducible Factor 1 alpha Subunitmedicine.diseasePhenotypeCell HypoxiaRecombinant ProteinsOxygenCell Transformation Neoplasticmedicine.anatomical_structureOncologyHematinicsHemoglobinmedicine.symptombusinessPerfusionThe Oncologist
researchProduct

Donors with KIR-Bx Haplotypes Improve Outcome of Unrelated Hematopoietic Stem Cell Transplantation for Recipients with a Myeloid Malignant Disease an…

2015

relapse, or transplant related mortality (TRM) (p1⁄40.2, p1⁄40.1, p1⁄40.08, respectively). To investigate why higher CPSS scores were associated with higher mortality, we performed analysis restricted to patients with relapse following HCT. Those with intermediate-2/high riskhadnearly two-fold increase in riskof death after relapse compared to thosewith low/intermediate1 CPSS scores. Corresponding rates for low/intermediate-1 risk groups,OSat1year, 3years, and5yearswere61%,48%, and44% respectivelyand for intermediate-2/high riskgroupswere 38%, 32%, and19%respectively.OSofpatientswho receivedpre-HCT treatment with hypomethylating agents, chemotherapy, or both was not different compared to th…

OncologyChemotherapymedicine.medical_specialtyTransplantationMyeloidbusiness.industrymedicine.medical_treatmentHaplotypeHematopoietic stem cell transplantationTransplant-Related MortalityHematologyLigand (biochemistry)Phenotype3. Good healthmedicine.anatomical_structureInternal medicinemedicineBone marrowbusinessBiology of Blood and Marrow Transplantation
researchProduct

Prognostic value of the immunohistochemical detection of epithelial-mesenchymal transition biomarkers in oral epithelial dysplasia : a systematic rev…

2019

Background Oral potentially malignant disorders (OPMDs) comprise a range of clinical-pathological alterations that are frequently characterized as architectural and cytological derangements upon histological analysis. Epithelial-mesenchymal transition (EMT) has been proposed as a critical mechanism for the acquisition of the malignant phenotype in neoplastic epithelial processes. This study aims to systematically review the current findings on the immunohistochemical expression of epithelial-mesenchymal transition markers in oral potentially malignant disorders and to evaluate their possible application as biomarkers associated with the progression of oral epithelial dysplasias. Material an…

OncologyEpithelial dysplasiamedicine.medical_specialtyEpithelial-Mesenchymal TransitionReviewCochrane LibraryInternal medicineBiomarkers TumorMedicineEpithelial–mesenchymal transitionStage (cooking)General DentistryMalignant phenotypeOral Medicine and Pathologybusiness.industryMechanism (biology)Prognosis:CIENCIAS MÉDICAS [UNESCO]Epitheliummedicine.anatomical_structureOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASImmunohistochemistrySurgerybusinessBiomarkers
researchProduct

Malignancy Risk Models for Oral Lesions

2013

Objectives: The aim of this work was to assess risk habits, clinical and cellular phenotypes and TP53 DNA changes in oral mucosa samples from patients with Oral Potentially Malignant Disorders (OPMD), in order to create models that enable genotypic and phenotypic patterns to be obtained that determine the risk of lesions becoming malignant. Study Design: Clinical phenotypes, family history of cancer and risk habits were collected in clinical histories. TP53 gene mutation and morphometric-morphological features were studied, and multivariate models were applied. Three groups were estabished: a) oral cancer (OC) group (n=10), b) OPMD group (n=10), and c) control group (n=8). Results: An avera…

OncologyMalePathologyGenotypeTP53Family historyYoung adultMouth neoplasmCiencias Médicas y de la SaludAged 80 and overpublic health//purl.org/becyt/ford/3.1 [https]Middle Aged:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludMedicina BásicaUNESCO::CIENCIAS MÉDICASOPMD//purl.org/becyt/ford/3 [https]FemaleMouth NeoplasmsRisk assessmentAdultmedicine.medical_specialtyGenética HumanaContext (language use)OdontologíaMalignancyRisk AssessmentYoung AdultInternal medicinemedicineHumansGeneral DentistryAgedOral Medicine and PathologyModels Statisticalbusiness.industryCancermedicine.diseaseGenes p53Cross-Sectional StudiesOtorhinolaryngologyORAL CANCERTP53; ORAL POTENTIALLY MALIGNANT DISORDERS; RISK FACTORS; GENOTYPE; PHENOTYPEMutationSurgeryResearch-ArticlebusinessMouth DiseasesMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct

A genomewide association study of smoking relapse in four European population-based samples.

2013

OBJECTIVES: Genomewide association studies (GWAS) have identified clear evidence of genetic markers for nicotine dependence. Other smoking phenotypes have been tested, but the results are less consistent. The tendency to relapse versus the ability to maintain long-term abstinence has received little attention in genetic studies; thus, our aim was to provide a better biological understanding of this phenotype through the identification of genetic loci associated with smoking relapse. METHODS: We carried out a GWAS on data from two European population-based collections, including a total of 835 cases (relapsers) and 990 controls (abstainers). Top-ranked findings from the discovery phase were …

OncologyMalemedicine.medical_specialtymedia_common.quotation_subjectGenome-wide association studyDiseasePolymorphism Single NucleotideWhite PeopleMeta-Analysis as TopicPolymorphism (computer science)RecurrenceInternal medicineGeneticsmedicineHumansALSPAC; genetics; KORA; PsyCoLaus; SHIP; smokingGeneBiological PsychiatryGenetics (clinical)media_commonDemographyGeneticsbusiness.industrySmokingAbstinenceMiddle AgedPhenotypePsychiatry and Mental healthGenetic markerCase-Control StudiesGenomewide associationFemalebusinessGenome-Wide Association StudyPsychiatric genetics
researchProduct

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of r…

2015

BackgroundAcquired resistance to BRAF inhibitors (BRAFi) is a near-universal phenomenon caused by numerous genetic and non-genetic alterations. In this study, we evaluated the spectrum, onset, pattern of progression, and subsequent clinical outcomes associated with specific mechanisms of resistance.MethodsWe compiled clinical and genetic data from 100 patients with 132 tissue samples obtained at progression on BRAFi therapy from 3 large, previously published studies of BRAFi resistance. These samples were subjected to whole-exome sequencing and/or polymerase chain reaction-based genetic testing.ResultsAmong 132 samples, putative resistance mechanisms were identified in 58%, including NRAS o…

OncologyNeuroblastoma RAS viral oncogene homologMaleCancer ResearchSkin NeoplasmsTime FactorsResistanceDNA Mutational AnalysisDrug ResistanceMedizinKaplan-Meier EstimateBioinformaticsmedicine.disease_causeRisk Factors2.1 Biological and endogenous factorsAetiologyVemurafenibMelanomaCancerMutationTumorDabrafenibMelanomaAcquiredMiddle AgedPhenotypeEuropePhenotypeTreatment OutcomeSpliceOncologyMeta-analysisPublic Health and Health ServicesDisease ProgressionFemalemedicine.drugSignal TransductionProto-Oncogene Proteins B-rafmedicine.medical_specialtyOncology and CarcinogenesisNRASAntineoplastic AgentsBiologyDisease-Free SurvivalArticleBRAFMEK1Clinical ResearchInternal medicineGeneticsmedicineBiomarkers TumorHumansGenetic Predisposition to DiseaseOncology & CarcinogenesisProtein Kinase InhibitorsProportional Hazards ModelsProportional hazards modelAustraliaDabrafenibmedicine.diseaseMAPKUnited StatesMeta-analysisVemurafenibDrug Resistance NeoplasmMutationNeoplasmBiomarkersEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Peripheral neuroblastic tumors with genotype-phenotype discordance: A report from the Children's Oncology Group and the International Neuroblastoma P…

2012

Background Of 4,706 peripheral neuroblastic tumors (pNTs) registered on the Children’s Cancer Group and Children’s Oncology Group Neuroblastoma Study between 1989 and 2010, 51 cases (1.1%) had genotype-phenotype discordance characterized by MYCN amplification (indicating poor prognosis) and Favorable Histology (indicating better prognosis).

OncologyPathologymedicine.medical_specialtybusiness.industryCancerHematologymedicine.diseaseNeuroblastic TumorN-Myc Proto-Oncogene ProteinGenotype phenotypePeripheralOncologyNeuroblastomaInternal medicinePediatrics Perinatology and Child HealthMycn amplificationMedicineImmunohistochemistrybusinessneoplasmsPediatric Blood & Cancer
researchProduct

Clinical Applications, Pitfalls, and Uncertainties of Thrombin Generation in the Presence of Platelets

2019

Platelet-dependent thrombin generation is a helpful tool to assess ex vivo the interaction between platelets and plasma coagulation factors in the initiation, amplification, and inhibition of thrombin generation (TG). This review article discusses the most relevant available data on the clinical applications of fluorogenic TG, the most widely used TG assay, performed in the presence of platelets, i.e., in platelet-rich plasma. With respect to prothrombotic states, arterial hypertension and obesity were the most prominent cardiovascular conditions linked to increased platelet-dependent TG. In addition, platelet-associated hypercoagulability, assessed by the TG assay, has been shown in indivi…

Oncologycardiovascular risk factorsmedicine.medical_specialtyBLEEDING PHENOTYPElcsh:MedicineReview030204 cardiovascular system & hematologyHYPERCOAGULABILITYACTIVATION03 medical and health sciences0302 clinical medicineInternal medicinehemophiliamedicineVon Willebrand diseasePlateletSEVERE HEMOPHILIA-AthrombosisVENOUS THROMBOEMBOLISMRICH PLASMAbiologybusiness.industryCALIBRATED AUTOMATED THROMBOGRAMlcsh:RRECOMBINANT FACTOR VIIAGeneral Medicinemedicine.diseasebleedingThrombosisFACTOR-V DEFICIENCYcardiovascular diseasesBleeding diathesisCoagulationRecombinant factor VIIathrombin generationOBESITYplateletsbiology.proteinBiomarker (medicine)businessvon Willebrand diseaseEx vivo030215 immunologyJournal of Clinical Medicine
researchProduct

ER-/PgR+ breast cancer is a separate entity characterized by distinct phenotype: Comprehensive reevaluation of cases from Polish and Hungarian center…

2020

e12554 Background: ER negative (-)/PgR positive (+) breast cancer (BC) is very uncommon and questioned by many experts. We comprehensively reevaluated ER-/PgR+ BCs in the large cohort from Polish and Hungarian centers. Methods: FFPE blocks from 105 ER-/PgR+ tumors (45 breast biopsies and 64 post-operative samples from tumors not exposed to systemic therapy) were collected from 10 Polish and 3 Hungarian centers. In 60 cases available original slides with ER/PgR staining underwent reevaluation by 3 pathologists (MK, RP, WB) for ER and PgR expression by ASCO/CAP criteria. Subsequently, all samples were stained with 3 antibodies against ER (Dako monoclonal (MC) mouse anti-ERα, clone 1D5; Dako …

Oncologyendocrine systemCancer Researchmedicine.medical_specialtybusiness.industryPGR Positivemedicine.diseaseER NegativePhenotypeLarge cohortBreast cancerOncologyInternal medicineMedicineskin and connective tissue diseasesbusinessSeparate legal entityJournal of Clinical Oncology
researchProduct